

Develop ENB-003 through Ph2 for primary indication(s) (non-CNS melanoma, ovarian CA, and pancreatic CA) then seek asset acquisition by big pharma partner

01

Develop ENB-004 to expand into other ETBR+ indications

02

Develop novel inhibitors of T-regs and caspase-8 inhibitors

04

03

Develop for ENB-005/ENB-006 to treat CNS malignancies: CNS metastases, CNS lymphoma and glioblastoma.